Iofina plc (IOF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iofina plc (IOF) has a cash flow conversion efficiency ratio of 0.166x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX9.23 Million ≈ $1.12K USD) by net assets (GBX55.70 Million ≈ $6.78K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Iofina plc net asset quality index to measure how much of total assets are equity-financed.
Iofina plc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Iofina plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Iofina plc to evaluate the quality of earnings relative to operating cash generation.
Iofina plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iofina plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JZ Capital Partners Ltd
LSE:JZCP
|
0.064x |
|
Asia Pacific Investama Tbk PT
JK:MYTX
|
0.008x |
|
Ellen AB (publ)
ST:ELN
|
-0.130x |
|
Scinai Immunotherapeutics Ltd
NASDAQ:SCNI
|
-0.123x |
|
INFINITII AI INC.
F:Y31
|
0.085x |
|
Aptitude Software Group PLC
LSE:APTD
|
-0.016x |
|
Urban-Gro Inc
NASDAQ:UGRO
|
0.056x |
|
AVRO INDIA LIMITED
NSE:AVROIND
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Iofina plc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Iofina plc from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see IOF stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX55.70 Million ≈ $6.78K |
GBX11.10 Million ≈ $1.35K |
0.199x | -17.37% |
| 2024-12-31 | GBX47.79 Million ≈ $5.81K |
GBX11.53 Million ≈ $1.40K |
0.241x | +25.93% |
| 2023-12-31 | GBX44.75 Million ≈ $5.44K |
GBX8.57 Million ≈ $1.04K |
0.192x | +31.03% |
| 2022-12-31 | GBX37.97 Million ≈ $4.62K |
GBX5.55 Million ≈ $675.40 |
0.146x | -44.50% |
| 2021-12-31 | GBX29.96 Million ≈ $3.65K |
GBX7.89 Million ≈ $960.23 |
0.263x | +44.09% |
| 2020-12-31 | GBX20.66 Million ≈ $2.51K |
GBX3.78 Million ≈ $459.43 |
0.183x | +4.82% |
| 2019-12-31 | GBX19.23 Million ≈ $2.34K |
GBX3.35 Million ≈ $408.05 |
0.174x | -47.79% |
| 2018-12-31 | GBX5.95 Million ≈ $723.66 |
GBX1.99 Million ≈ $241.74 |
0.334x | +980.27% |
| 2017-12-31 | GBX6.97 Million ≈ $847.55 |
GBX-264.35K ≈ $-32.16 |
-0.038x | -240.48% |
| 2016-12-31 | GBX16.70 Million ≈ $2.03K |
GBX451.20K ≈ $54.90 |
0.027x | +281.39% |
| 2015-12-31 | GBX20.75 Million ≈ $2.52K |
GBX-308.97K ≈ $-37.59 |
-0.015x | -78.21% |
| 2014-12-31 | GBX23.49 Million ≈ $2.86K |
GBX-196.29K ≈ $-23.88 |
-0.008x | +50.11% |
| 2013-12-31 | GBX28.81 Million ≈ $3.50K |
GBX-482.50K ≈ $-58.71 |
-0.017x | +88.09% |
| 2012-12-31 | GBX31.25 Million ≈ $3.80K |
GBX-4.39 Million ≈ $-534.71 |
-0.141x | -183.32% |
| 2011-12-31 | GBX25.77 Million ≈ $3.14K |
GBX-1.28 Million ≈ $-155.66 |
-0.050x | +68.66% |
| 2010-12-31 | GBX23.96 Million ≈ $2.91K |
GBX-3.80 Million ≈ $-461.77 |
-0.158x | +26.13% |
| 2009-12-31 | GBX29.53 Million ≈ $3.59K |
GBX-6.33 Million ≈ $-770.44 |
-0.214x | -751.82% |
| 2008-12-31 | GBX23.72 Million ≈ $2.89K |
GBX780.53K ≈ $94.97 |
0.033x | +123.36% |
| 2007-12-31 | GBX2.56 Million ≈ $311.75 |
GBX-360.93K ≈ $-43.91 |
-0.141x | -101.75% |
| 2006-12-31 | GBX-58.78K ≈ $-7.15 |
GBX-474.13K ≈ $-57.69 |
8.067x | -- |
About Iofina plc
Iofina plc, together with its subsidiaries, explores for, develops, and produces iodine and halogen-based specialty chemical derivatives from oil and gas operations in North America, Asia, South America, Europe, and internationally. The company offers iodides, chlorides, and fluorides; and iodine used for animal care and health, biocides and catalysts, disinfectants, fungicide, specialty intermed… Read more